Nifty
:
25461.00
Sensex
:
83432.89
55.70 (0.22%)
193.42 (0.23%)
Nifty
Sensex
:
:
25461.00
83432.89
55.70 (0.22%)
193.42 (0.23%)

JB Chemicals & Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
63/99

BSE: 506943 | NSE: JBCHEPHARM

NSE BSE
1638.10
04-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1632.1
  •  1646.4
  •  1631
  •  1639.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1117679
  •  1831941630.8
  •  2030
  •  1385.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 25,561.60
  • 38.75
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 25,445.95
  • 0.95%
  • 7.45

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.84%
  • 0.50%
  • 13.28%
  • FII
  • DII
  • Others
  • 18.3%
  • 18.03%
  • 2.05%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.78
  • 14.44
  • 12.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.36
  • 18.77
  • 10.46

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.59
  • 15.23
  • 12.77

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 27.97
  • 38.69
  • 44.81

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.31
  • 7.17
  • 8.06

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.30
  • 23.26
  • 26.94

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
35.66
42.36
51.52
60.52
P/E Ratio
45.94
38.67
31.80
27.07
Revenue
3449
3918
4388
4909
EBITDA
892
1070
1198
1391
Net Income
553
660
815
947
ROA
14.6
16
17.8
18.9
P/B Ratio
8.81
7.43
6.34
5.39
ROE
20.45
20.75
21.48
21.55
FCFF
634
800
754
258
FCFF Yield
2.48
3.13
2.95
1.01
Net Debt
-83
-419
-1223
-991
BVPS
185.98
220.51
258.41
303.94

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
949.48
861.73
10.18%
963.49
844.51
14.09%
1,000.62
881.74
13.48%
1,004.40
896.20
12.07%
Expenses
723.04
663.61
8.96%
708.98
621.39
14.10%
730.10
638.20
14.40%
724.03
664.09
9.03%
EBITDA
226.44
198.12
14.29%
254.51
223.12
14.07%
270.52
243.54
11.08%
280.37
232.11
20.79%
EBIDTM
23.85%
22.99%
26.42%
26.42%
27.04%
27.62%
27.91%
25.90%
Other Income
14.48
16.63
-12.93%
8.00
7.35
8.84%
9.95
7.66
29.90%
5.89
5.63
4.62%
Interest
1.45
9.41
-84.59%
2.58
12.49
-79.34%
2.06
10.37
-80.14%
5.64
12.06
-53.23%
Depreciation
46.44
40.74
13.99%
41.94
34.03
23.24%
41.88
32.17
30.18%
40.78
31.38
29.96%
PBT
193.03
164.60
17.27%
217.99
183.95
18.51%
236.53
208.66
13.36%
239.84
194.30
23.44%
Tax
47.34
38.44
23.15%
55.50
50.38
10.16%
61.96
58.07
6.70%
63.01
51.98
21.22%
PAT
145.69
126.16
15.48%
162.49
133.57
21.65%
174.57
150.59
15.92%
176.83
142.32
24.25%
PATM
15.34%
14.64%
16.86%
15.82%
17.45%
17.08%
17.61%
15.88%
EPS
9.36
8.13
15.13%
10.45
8.62
21.23%
11.24
9.72
15.64%
11.39
9.19
23.94%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
3,917.99
3,484.18
3,149.28
2,424.24
2,042.52
1,774.73
1,643.20
1,413.77
1,368.32
1,231.58
1,144.21
Net Sales Growth
12.45%
10.63%
29.91%
18.69%
15.09%
8.00%
16.23%
3.32%
11.10%
7.64%
 
Cost Of Goods Sold
1,316.55
1,182.05
1,168.20
842.93
701.50
630.80
596.46
542.41
552.00
491.41
341.40
Gross Profit
2,601.44
2,302.13
1,981.08
1,581.31
1,341.02
1,143.93
1,046.74
871.35
816.32
740.17
802.81
GP Margin
66.40%
66.07%
62.91%
65.23%
65.66%
64.46%
63.70%
61.63%
59.66%
60.10%
70.16%
Total Expenditure
2,886.15
2,591.70
2,453.53
1,881.63
1,486.35
1,397.15
1,337.36
1,214.64
1,135.93
1,025.55
964.09
Power & Fuel Cost
-
88.08
91.54
71.47
62.60
61.54
63.29
58.28
54.89
55.28
53.02
% Of Sales
-
2.53%
2.91%
2.95%
3.06%
3.47%
3.85%
4.12%
4.01%
4.49%
4.63%
Employee Cost
-
601.41
543.45
439.24
340.60
322.92
288.18
251.10
217.34
175.31
159.56
% Of Sales
-
17.26%
17.26%
18.12%
16.68%
18.20%
17.54%
17.76%
15.88%
14.23%
13.94%
Manufacturing Exp.
-
234.82
210.91
194.00
148.68
140.70
150.49
139.83
131.45
119.35
223.53
% Of Sales
-
6.74%
6.70%
8.00%
7.28%
7.93%
9.16%
9.89%
9.61%
9.69%
19.54%
General & Admin Exp.
-
119.69
110.09
100.46
56.35
48.14
52.97
53.96
42.26
34.82
32.46
% Of Sales
-
3.44%
3.50%
4.14%
2.76%
2.71%
3.22%
3.82%
3.09%
2.83%
2.84%
Selling & Distn. Exp.
-
268.40
233.96
161.80
113.22
116.95
113.59
87.44
78.27
72.72
75.13
% Of Sales
-
7.70%
7.43%
6.67%
5.54%
6.59%
6.91%
6.18%
5.72%
5.90%
6.57%
Miscellaneous Exp.
-
97.24
95.38
71.72
63.38
76.11
72.38
81.61
59.72
76.65
75.13
% Of Sales
-
2.79%
3.03%
2.96%
3.10%
4.29%
4.40%
5.77%
4.36%
6.22%
6.91%
EBITDA
1,031.84
892.48
695.75
542.61
556.17
377.58
305.84
199.13
232.39
206.03
180.12
EBITDA Margin
26.34%
25.62%
22.09%
22.38%
27.23%
21.28%
18.61%
14.09%
16.98%
16.73%
15.74%
Other Income
38.32
41.67
9.94
40.07
116.62
50.90
41.44
55.29
50.16
56.65
10.89
Interest
11.73
44.33
36.05
5.12
7.24
3.26
4.65
3.49
5.37
10.65
6.82
Depreciation
171.04
138.32
114.41
72.66
68.67
66.32
55.64
56.97
47.22
41.22
38.64
PBT
887.39
751.51
555.23
504.90
596.89
358.89
286.99
193.95
229.94
210.82
145.55
Tax
227.81
198.88
145.23
118.86
148.36
76.50
93.02
55.23
45.55
49.58
45.14
Tax Rate
25.67%
26.46%
26.16%
23.54%
24.86%
21.93%
32.41%
28.48%
19.81%
23.52%
31.01%
PAT
659.58
552.63
409.84
385.36
447.96
272.04
193.47
138.34
184.06
161.14
100.41
PAT before Minority Interest
659.58
552.63
410.01
386.04
448.52
272.39
193.97
138.72
184.40
161.24
100.41
Minority Interest
0.00
0.00
-0.17
-0.68
-0.56
-0.35
-0.50
-0.38
-0.34
-0.10
0.00
PAT Margin
16.83%
15.86%
13.01%
15.90%
21.93%
15.33%
11.77%
9.79%
13.45%
13.08%
8.78%
PAT Growth
19.35%
34.84%
6.35%
-13.97%
64.67%
40.61%
39.85%
-24.84%
14.22%
60.48%
 
EPS
42.36
35.49
26.32
24.75
28.77
17.47
12.43
8.89
11.82
10.35
6.45

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
2,923.33
2,480.35
2,134.12
1,809.72
1,435.49
1,480.12
1,441.56
1,363.67
1,183.84
994.87
Share Capital
15.52
15.48
15.46
15.46
15.46
16.05
16.71
16.96
16.96
16.96
Total Reserves
2,767.97
2,343.26
2,056.01
1,794.27
1,420.03
1,464.08
1,424.84
1,346.70
1,166.87
977.91
Non-Current Liabilities
465.96
992.03
475.34
72.47
62.72
64.84
45.66
26.98
31.02
32.62
Secured Loans
23.64
383.22
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.40
Long Term Provisions
287.66
494.68
410.43
12.57
7.39
5.73
9.67
12.56
10.43
12.03
Current Liabilities
1,287.76
625.70
455.16
686.57
516.19
781.54
736.50
693.46
797.22
459.75
Trade Payables
356.31
238.65
224.48
186.92
167.97
117.37
110.39
98.98
90.85
77.51
Other Current Liabilities
435.75
240.33
81.31
89.82
102.67
93.10
119.75
122.15
138.73
103.74
Short Term Borrowings
15.34
28.02
26.32
32.64
29.49
25.80
29.29
48.86
193.02
126.88
Short Term Provisions
480.35
118.71
123.06
377.17
216.06
545.27
477.06
423.47
374.61
151.62
Total Liabilities
4,677.05
4,098.08
3,069.11
2,572.47
2,016.90
2,329.30
2,226.49
2,086.29
2,013.75
1,487.24
Net Block
2,004.40
1,901.01
1,276.99
633.65
651.26
620.93
639.50
679.44
440.22
328.56
Gross Block
2,835.23
2,607.77
1,876.20
1,182.55
1,177.43
1,084.83
1,053.76
1,038.55
753.75
601.67
Accumulated Depreciation
830.83
706.76
599.21
548.90
526.17
463.89
414.25
359.10
313.53
273.11
Non Current Assets
2,404.17
2,498.80
1,744.51
678.57
740.83
740.80
717.89
879.15
831.58
586.31
Capital Work in Progress
76.40
55.15
18.68
25.57
16.17
15.09
17.40
3.76
134.89
55.17
Non Current Investment
23.71
13.78
12.72
12.91
69.45
95.88
49.96
185.84
231.42
184.83
Long Term Loans & Adv.
293.64
514.35
435.07
5.62
3.59
8.31
10.15
9.43
22.63
17.74
Other Non Current Assets
6.03
14.51
1.04
0.82
0.36
0.59
0.88
0.67
2.43
0.00
Current Assets
2,272.87
1,599.29
1,324.61
1,893.89
1,276.08
1,588.51
1,508.59
1,207.14
1,182.16
900.94
Current Investments
364.65
192.18
0.00
664.97
333.81
360.65
383.77
224.96
247.28
366.78
Inventories
502.51
430.48
409.96
347.45
274.67
243.76
213.73
200.17
187.98
150.27
Sundry Debtors
686.92
575.80
555.69
389.02
345.43
308.22
300.73
265.97
272.64
262.35
Cash & Bank
95.54
78.81
58.53
30.85
30.95
36.80
29.92
13.39
12.90
25.19
Other Current Assets
623.25
44.91
57.43
45.95
291.22
639.08
580.44
502.66
461.34
96.35
Short Term Loans & Adv.
590.16
277.09
243.00
415.66
272.33
605.85
567.50
488.30
458.83
95.97
Net Current Assets
985.12
973.58
869.45
1,207.33
759.88
806.97
772.10
513.68
384.94
441.19
Total Assets
4,677.04
4,098.09
3,069.12
2,572.46
2,016.91
2,329.31
2,226.48
2,086.29
2,013.74
1,487.25

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
800.61
625.61
170.13
314.78
275.75
194.33
122.92
201.13
140.41
126.66
PBT
751.51
555.23
504.90
596.89
348.89
286.99
193.95
229.94
212.23
145.55
Adjustment
187.22
195.78
102.27
-46.17
7.95
23.72
16.91
13.11
-1.40
38.51
Changes in Working Capital
-5.64
-29.92
-302.42
-94.21
9.70
-51.47
-47.07
5.92
-16.96
-19.52
Cash after chg. in Working capital
933.10
721.09
304.75
456.50
366.55
259.24
163.79
248.97
193.88
164.53
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-132.49
-95.48
-134.62
-141.72
-90.80
-64.91
-40.87
-47.84
-53.47
-37.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-403.83
-961.79
2.32
-230.68
23.93
-27.67
-20.68
-45.31
-27.62
-111.89
Net Fixed Assets
-247.88
-761.82
-681.80
-12.39
-94.42
-29.82
-29.56
-152.86
-187.76
-69.64
Net Investments
-192.30
-193.24
665.16
-274.62
53.26
-22.80
-22.92
67.89
-14.16
-61.38
Others
36.35
-6.73
18.96
56.33
65.09
24.95
31.80
39.66
174.30
19.13
Cash from Financing Activity
-385.49
356.54
-138.39
-87.42
-306.05
-155.74
-59.52
-183.84
-99.62
-1.39
Net Cash Inflow / Outflow
11.30
20.36
34.07
-3.31
-6.38
10.92
42.72
-28.02
13.17
13.38
Opening Cash & Equivalents
76.93
56.54
22.47
25.75
32.14
21.24
-21.47
6.54
-5.46
11.81
Closing Cash & Equivalent
88.22
76.93
56.54
22.47
25.75
32.14
21.24
-21.47
9.42
25.19

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
179.35
152.42
134.02
234.17
185.75
184.47
172.50
160.77
139.57
117.31
ROA
12.60%
11.44%
13.69%
19.55%
12.53%
8.52%
6.43%
8.99%
9.21%
7.08%
ROE
21.49%
18.51%
19.89%
27.64%
18.69%
13.28%
9.89%
14.48%
14.80%
9.86%
ROCE
25.23%
22.79%
25.48%
36.53%
23.71%
19.59%
13.70%
16.87%
17.72%
13.49%
Fixed Asset Turnover
1.32
1.46
1.63
1.73
1.57
1.54
1.35
1.53
1.82
2.03
Receivable days
63.93
63.16
69.29
65.62
67.22
67.63
73.15
71.84
79.28
78.41
Inventory Days
47.24
46.91
55.55
55.59
53.31
50.81
53.43
51.77
50.12
44.83
Payable days
91.86
72.35
89.07
92.33
38.74
32.21
33.66
32.86
32.45
27.82
Cash Conversion Cycle
19.31
37.72
35.77
28.88
81.79
86.23
92.93
90.75
96.95
95.43
Total Debt/Equity
0.13
0.23
0.01
0.02
0.02
0.02
0.02
0.04
0.16
0.13
Interest Cover
17.95
16.40
99.60
83.43
108.09
62.74
56.54
43.81
20.80
22.33

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • J. B. Chemicals & Pharmaceuticals gets USFDA’s nod for Amitriptyline Hydrochloride Tablets
    25th Jun 2025, 09:19 AM

    Amitriptyline Hydrochloride Tablets is indicated for relief of symptoms of depression

    Read More
  • J.B. Chemicals & Pharmaceuticals secures USFDA’s approval for Bisoprolol Tablets
    21st Apr 2025, 14:21 PM

    Bisoprolol Tablets is indicated in the management of hypertension

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.